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ABSTRACT 
     Contrast agents are of great importance in clinical applications of Magnetic Resonance 
Imaging (MRI) to improve the contrast of internal body structures and to obtain tissue-specific 
image. However, current approved contrast agents still have limitations including low relaxivity, 
low specificity and uncontrolled blood circulation time, which motivated researchers to develop 
novel contrast agents with higher relaxivity, improved targeting abilities and optimal retention 
time. This thesis uses animal experimental data from Dr. Jenny J. Yang’s lab at the Department 
of Chemistry in Georgia State University to study effects of a class of newly designed protein-
based MRI contrast agents (ProCAs). Models for the longitudinal data on MRI intensity are 
constructed to evaluate the efficiency of different MRI contrast agents. Statistically significant 
results suggest that ProCA1B14 has the great potential to be a tumor specific contrast agent and 
ProCA32 could be a promising MRI contrast agent for the liver imaging in clinical applications. 
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CHAPTER 1 INTRODUCTION 
1.1 MRI and MRI Contrast Agents 
1.1.1 MRI 
In 1952, Herman Carr firstly produced a one-dimensional Magnetic Resonance Imaging 
(MRI) image as reported in his Harvard PhD thesis [1]. Since then, the technique of MRI has 
been studied by numerous scientists, and breath-taking progresses have been achieved along the 
study time. The clinical application of MRI in the early 1980s revolutionized diagnostic imaging. 
Nowadays, MRI scanning is a three-dimensional medical imaging procedure that uses strong 
magnetic fields and radio waves to generate cross-sectional images of organs and internal 
structures in the body. MRI is a noninvasive technique since it does not require the use of 
radioactive probes, which significantly reduces the potential radioactive exposure caused side-
effects. In addition to its superior soft tissue contrast, MRI has high resolution compared with 
other techniques, such as positron emission tomography (PET) and single-photon emission 
computed tomography (SPECT). Given these great advantages, MRI has become one of the most 
prevalent imaging techniques in clinical and preclinical tests [2-4]. It has been widely applied in 
diagnosis of different types of tumors, cardiovascular diseases, inflammatory diseases, 
degenerative diseases, musculoskeletal disorders and other diseases [5-8].       
1.1.2 Contrast Agent 
MRI contrast agents are a group of media that are used to increase the difference in 
contrast between tissues by changing the tissue relaxation time and thus improve the visibility of 
internal body structures in MRI. Since MRI has relatively low sensitivity compared to PET and 
SPECT, in order to enhance the contrast and sensitivity of MRI imaging, about 35% of clinical 
MRI scans requires the injection of MRI contrast agents [9]. Current MRI contrast agents are 
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based on paramagnetic, ferromagnetic or super paramagnetic metal ions. All MRI contrast agents 
can decrease both longitudinal (T1) and transverse (T2) relaxation times of water protons. One 
type of MRI contrast agents is called T1-weighted MRI contrast agent. It can decrease T1 and T2 
relaxation times of water protons at the same level. Another type is called T2-weighted contrast 
agent, which causes much shorter T2 than T1 [10]. T1-weighted contrast agents are more 
preferable due to brighter contrast generating capabilities. Gadolinium (Gd
3+
), a lanthanide metal 
with seven unpaired electrons, long electron spin relaxation time, and high magnetic moment, is 
one of the most widely used ions in T1-weighted MRI contrast agents [11-14]. 
1.1.3 Current Approved Clinical Contrast Agents 
At present, clinically approved Gd
3+
-based MRI contrast agents are all formed by one 
Gd
3+
 encapsulated by organic chelators. According to the charge and structures of chelators, 
currently used Gd
3+
 MRI contrast agents can be categorized into four groups,  including ionic 
linear contrast agents (such as Eovist), non-ionic linear contrast agents, ionic cyclic and non-
ionic cyclic contrast agents.  
Eovist is one of the FDA approved MRI contrast agents. Eovist is robustly uptake by 
hepatocyte and eliminated by both renal pathway and hepatic-intestinal pathway, approximately 
50% of injected Eovist is excreted by kidney, whereas the other 50% is actively transported into 
the liver cells and then excreted via the biliary system, therefore, it’s widely used  for the 
imaging of liver and biliary diseases in practice [15, 16]. In our study, Eovist was used as a 
control group to compare with one of our new designed protein-based contrast agents, ProCA32. 
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1.1.4 New Designed Contrast Agents by Researchers in the Department of Chemistry of 
GSU 
 Researchers in the Department of Chemistry of Georgia State University have developed 
a new class of the protein-based MRI contrast agents (ProCAs) including ProCA1, ProCA1B14 
and ProCA32, etc.  
ProCA1, previously named as CA1.CD2, was designed by creating high coordination 
Gd
3+
 binding sites in a stable host protein, domain 1 of rat CD2, with a strong metal binding 
affinity and selectivity, as well as greater relaxivity enhancement [17]. Because the inner sphere, 
2
nd
 sphere coordination water, rotational correlation time, and water exchange rate of ProCA 
were optimized, ProCA1 has extremely high relaxivity. The relaxivity of ProCA1 is 117 mM
-1
s
-1
 
at 1.5 T, which is at least 20 times greater than that of clinical MRI contrast agents, such as Gd-
DTPA. High relaxivity makes ProCA1 extremely sensitive and effective to change MRI signal in 
vitro and in vivo. One limitation of ProCA1 for cancer imaging is that ProCA1 does not have 
cancer targeting moiety, which makes it impossible to target cancer biomarkers.  
ProCA1B14 is a further advancement of ProCA1 with an insertion of bombesin at its 52 
position with a flexible linker. Bombesin is a 14-amino acid peptide and one of its known 
homologs in mammals is called gastrin-releasing peptide (GRP). Bombesin acts through its cell 
surface gastrin-releasing peptide receptors (GRPR), which are expressed in very high levels in 
prostate cancer, small cell lung cancer and breast cancer cells [13, 18-21]. This new MRI 
contrast agent, ProCA1B14, is designed to be a tumor specific agent that is able to target 
biomarker GRPR using the peptide of bombesin, and has the potential capability of producing an 
MR image of specific cancers, such as prostate cancer. Figure 1.1 shows the model structure of 
ProCA1B14. The full sequence of bombesin peptide was inserted into the ProCA1 at 52G 
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position using grafting approach [13, 22-24]. Flexible linkers, such as GGSGG, were used to link 
ProCA1 and bombesin peptide, which give the peptide certain flexibility and maintain its three 
dimensional structure for molecular recognition. In addition, such design also better protect the 
peptide degradation by protease.  
 
Figure 1.1  Model structure of ProCA1.GRP. 
Model structure of ProCA1.GRP predicted by I-TASSER. The tumor targeting peptide (red), 
GRP, is grafted in ProCA1 (blue) with flexible linkers (yellow) [19]. 
 
PcoCA32 is the 3rd generation of ProCAs, which has two Gd
3+
 binding sites in a scaffold 
protein. The molecular weighted ProCA32 is around 12 kDa, which is similar to ProCA1. 
Compared with ProCA1, the metal binding affinity and metal selectivity of ProCA32 
dramatically improved. The Gd
3+
 binding affinity to ProCA32 is 2.79 ± 0.36 10
-22
 M (Xue, 
unpublished data), which is comparable with all clinically approved MRI contrast agents. 
ProCA32 has high liver distribution in the sinusoidal space. ProCA32 exhibits relaxivties per 
particle r1 of 66.8 mmol
-1
 s
-1
 and r2 of 89.2 mmol
-1 
s
-1
, which are about 10 fold greater than that 
of Eovist at 1.4 T. These properties made ProCA32 superior for the MRI of a series of liver 
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disease, which has impaired sinusoidal space and blood distribution in liver tissue. ProCA32 has 
a blood half-life of 2.8 hours. This property made ProCA32 also voluble for the image of blood 
abnormalities. Since ProCA32 also enhances kidney, this contrast agent can also be applied to 
evaluate kidney function and imaging kidney disease. 
 
1.2  Data Source and Experimental Design 
All the animal experimental data were collected from Dr. Jenny J. Yang’s laboratory in 
the Department of Chemistry in GSU, collaborated with Emory University and University of 
Georgia. Basically, there are 2 sets of data used in this thesis. First dataset is for testing the 
targeting capability of the developed GRP-targeting contrast agent ProCA1B14. In order to 
accomplish this, researchers generated a xenograft nude mouse cancer model. As showed in 
Figure 1.2, human prostate cancer cell line (PC3) tumor cells were planted on the right flank of 
the mouse and human lung adenocarcinoma epithelial cell line (H441) tumor cells were planted 
on the left side. MRI experiments were carried out when the tumor size reached around 1 
centimeter in diameter. MRI were collected at 7 T variant MRI scanner using spin echo sequence 
(TR = 400 ms, TE keep minimum, FOV 4 cm × 4 cm, matrix 128 × 128, slice thickness 1 mm). 
Contrast agents (0.025 mmol/kg ProCA1 or ProCA1B14) were injected to the mouse by tail vein 
and the intensity pre and post injection in both contrast agents groups were observed at time 
points 0 min, 10 min, 30 min, 1 day and 2 days. MR images were visualized by ImageJ software. 
To measure the tumor intensity, we first defined the region of interest (RIO) of MR imaging by 
circle PC3 tumor and H441 tumors from differences. We circled each tumor from 6 separate 
slices and measured the tumor intensity by imageJ software. Such intensity measurement was 
repeated in both tumors, before and after injection of ProCA1 or ProCA1B14 at 5 time points. 
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Figure 1.2 A xenograft nude mouse tumor model induced by PC3 and H441 tumor cells. 
 
Another dataset is to compare the MRI liver enhancement of Eovist and ProCA32 in mice 
under the T1-weighted spin echo sequence at 4.7 T (TR = 400 ms, TE = 11 ms, FOV 4 cm × 4 
cm, matrix 512 × 512, slice thickness= 1mm). With the injection of 0.0125 mmol/kg or 0.025 
mmol/kg of ProCA32 and 0.025 mmol/kg of Eovist through tail vein of the mouse, we observed 
the liver MR intensity at similar time occasions, which are pre-injection, around 10-17 minutes 
and 46-50 minutes after injection, respectively. The MRI intensity is a parameter to evaluate the 
efficiency of different MRI contrast agents. The MRI intensity were measured by ImageJ. 
Similar as ProCA1B14 section, we first selected several ROI at liver region by imageJ, and then 
measured the intensity of liver before and after injection of contrast agents at several time points 
of interest.   
 
1.3 Data Description 
In this thesis, two given datasets are all longitudinal data since the measurements of the 
same individuals are taken repeatedly through the study time. In a longitudinal study, individuals 
are measured repeatedly at different occasions or times. When number and timing of the repeated 
measures are the same for all individuals, study design is said to be “balanced” over time. For the 
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ProCA1 and ProCA1B14 data, two different contrast agents were considered as two groups and 
they were injected into the mice tumor model with two types of tumor cells, respectively.  For 
each type of cancer, there were five subjects in each group. For each subject, there were five time 
occasions including 0, 10 minutes, 30 minutes, 1440 minutes (1 day), 2880 minutes (2 days). 
Therefore, this dataset was balanced with not equally spaced time design. While for the ProCA32 
and Eovist dataset, observations were taken at similar time points, but not exactly the same. If we 
name the 0.025 mmol/kg of Eovist group as group 1 (control group), the 0.0125 mmol/kg of 
ProCA32 as group 2 and the 0.025 mmol/kg of ProCA32 as group 3, we can see that there were 
eight subjects in each group and for each subject, there were three records with different time 
occasions, which were pre injection, 10 minutes and 50 minutes post injection for group 1,  pre 
injection, 17 minutes and 48 minutes post injection for group 2, and  pre injection, 16 minutes 
and 46 minutes after injection for group 3, indicating that it is unbalanced data. We do not have 
any missing value for both datasets. 
 
1.4 Purpose of Study  
Although contrast agents are widely used in clinical diagnosis, current clinical contrast 
agents still have some limitations that need to be overcome, such as short half-life which limits 
the viable MRI time so that repeated dose injections may be required, low detection limits and 
low targeting specificity. Therefore, there is an urgent need for developing new MRI contrast 
agents with higher detection sensitivity, significantly improved relaxivity, optimal retention time 
and increased potential targeting capabilities. In this thesis, we utilized the animal experimental 
data from the Department of Chemistry, to achieve the following goals: 
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(1) To compare the MRI signal enhancement in PC3 and H441 tumor before and after 
injection of ProCA1 or ProCA1B14 in a nude mouse xenograft cancer model. Different time 
occasions are pre injection, 10 minutes, 30 minutes, 1 day and 2 days after the injection for both 
groups. 
(2) To compare the liver enhancement of MRI before and 10-17 and 46-50 minutes after 
the injection of ProCA32 with two different concentrations (0.0125 mmol/kg and 0.025 mmol/kg) 
and  0.025 mmol/kg of Eovist in mice.  
Ultimately, results from these comparisons can be used to evaluate the effect of the novel 
designed protein based liver contrast agent ProCA32 and to test whether ProCA1B14 can be 
applied to the targeted imaging by scanning specific cancer cells using MRI in the animal 
experimental phase. 
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CHAPTER 2 METHODS 
2.1 Basic Ideas for Analyzing Longitudinal Data 
Longitudinal data analysis requires more sophisticated statistical techniques because of 
its two main characteristics. One is that repeated measures on the same individual are usually 
intrinsically correlated, which violates the independence assumption that is the basis of many 
statistical techniques. Another one is that variability is often heterogeneous across the 
measurement occasions, that is, the variability of the outcome at the end of the study is often 
different from the variability at the start of the study. This violates the constant variance 
assumption that is the basis for standard linear regression techniques. Therefore, correlation and 
heterogeneous variability in longitudinal data must be accounted for in order to obtain valid 
inferences about change in response over time [26]. Instead of using ANOVA model to analyze 
longitudinal data, we consider extensions of the ANOVA model that account for the covariance. 
That is, rather than assuming that repeated observations of the same subject are independent, 
with homogeneous variance, we allow the repeated measurements to have an unknown 
covariance structure. To achieve this purpose, we can use the SAS procedure, PROC MIXED, an 
extension of PROC GLM which allows clusters of correlated observations [27, 28].  
For longitudinal data, basically, we have three main different questions concerning the 
mean response: 
(1) Is there a group × time interaction effect, that is, are the mean responses similar in the 
groups along the study time?  
(2) Is there a time effect? Assuming mean profiles are parallel, are the mean responses 
constant over time? 
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 (3) Is there a group effect? Assuming that the mean responses are parallel, are they also 
at the same level for different groups?  
 
Figure 2.1 Graphical representation of the null hypothesis of (a) no group × time interaction 
effect, (b) no time effect, and (c) no group effect [29]. 
 
For longitudinal data analysis, the primary goal of the study is to characterize the change 
in response over time and the factors that influence change, which is about the question 1, group 
× time interaction effect.  
2.2 General Linear Model for Longitudinal Data 
 If we consider a general linear regression model for changes in the mean response over 
time: 1 1 2 2 , 1, , ;ij ij ij p ijp ijY X X X j n         where 1, p  are unknown regression 
coefficients, ij are random errors with mean zero, and are expected to be correlated within 
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individuals. That is, '
'( , ) 0 ( )ij ijCov j j    . The following assumptions are needed for a linear 
regression model of longitudinal data: 
(1) Data represents random sample from the population. 
(2) Between different individuals, observations are independent, while repeated 
measurements of the same subject are not necessarily assumed to be independent. 
(3) The elements of the vector of repeated measures, 1, , ii inY Y , have a Multivariate 
Normal (MVN) Distribution, with means 
1 1 2 2( )ij ij ij ij ij p ijpE Y X X X X        and 
covariance matrix  . 
(4) If there are missing data, they can be assumed to be ignorable. 
2.3 Modeling Longitudinal Data 
Longitudinal data presents two aspects that require modeling: 
(1) Mean response over time. We need to fit a linear regression model that provides a 
good fit to the mean of the variable of interest. 
(2) Covariance among repeated measurements. We need to choose a covariance model 
that provides a good fit to the observed variances and covariances. 
2.3.1 Modeling the Mean  
There are two main methods used to model the mean response of longitudinal data. 
(1) Analysis of response profiles. We compare groups of subjects in terms of mean 
response profiles over time, where each observation time is considered as a categorical variable. 
The number of indicator variables for time is the number of time points minus one. It’s an useful 
and straightforward way for balanced longitudinal designs, with the timing of the repeated 
measures common to all individuals in the study, and with a single categorical covariate such as 
different treatments or exposure groups. It allows arbitrary patterns in the mean response over 
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time and the covariance. As a result, this method for longitudinal analysis has a certain 
robustness, since the potential bias due to misspecification of the models for the mean and 
covariance are assumed to be minimized. However, there are several drawbacks for this method. 
Firstly, it requires a balanced design so that this analysis is not suited for handling unbalanced 
measurements. Secondly, it does not consider the time order of the repeated measurements in a 
longitudinal study and may have a lower power to detect group differences in specific trends in 
the mean response over time. Thirdly, the number of estimated parameters grows rapidly with 
the number of measurement occasions (n). Therefore, this method is more suitable when the total 
number of subjects, N, is relatively large in comparison to the number of measurement occasions, 
n [30]. 
(2) Parametric or semi-parametric curves.  
We can fit parametric or semi-parametric curves to model the mean response of 
longitudinal data to describe the change of mean over time, where time is considered as 
continuous and  means are modeled as an explicit function of time [31]. Consequently, this 
method can be applied to highly unbalanced longitudinal designs. Compared with response 
profile analysis, this method is more appealing since that in many longitudinal studies the true 
underlying mean response process is likely to change over time in a relatively smooth, 
monotonically changing pattern. Also, since the tests of covariate effects focus only on a 
relatively narrow range of alternative hypotheses, the resulting tests of time trends and covariate 
effects will have greater power than the global tests in an analysis of response profiles. Finally, 
continuous time effect leads to decreasing of number of parameters so that a simple parametric 
curves provide a parsimonious description of changes in the mean response over time.  
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A possible trend for describing changes in the mean response over time is a straight line, 
where slope is directly interpreted as a constant rate of change in mean response for a single unit 
change in time. This model with linear trends for two groups is depicted graphically in Figure 2.2, 
where the two groups have different intercepts and slopes. 
 
Figure 2.2 Graphical representation of model with linear trends over time for two groups [29]. 
 
High order with time can be considered into the model when changes in the mean 
response over time are not simply linear, such as a model with quadratic trend over time, where 
the rate of change in the mean response is not constant but depends on time. This model with 
quadratic trends for two groups is graphically represented in Figure 2.3, where the two groups 
have different intercepts and distinct non-constant rates of change over time. 
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Figure 2.3 Graphical representation of model with quadratic trends over time for two groups 
[29]. 
 
In some cases, the mean response cannot be characterized by linear or quadratic trends 
model, for example, in some non-linear trends applications, the changing rate of mean responses 
are of much differences before or after certain time points. When this type of change pattern 
arises, we can consider linear spline models to handle it. The basic idea behind the linear spline 
model is that dividing time into series of segments and consider piecewise linear trends, having 
different slopes but joined at fixed times [32]. The slope changing points are called knots and 
resulting piecewise-linear curve is called a spline. Figure 2.4 depicted a linear spline model for 
two groups with a common knot at time point 2. We can see that the slopes of the two lines are 
discernibly different before and after the knot.  
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Figure 2.4 Graphical representation of linear splines model for two groups with a common knot 
at time 2 [29]. 
 
Here, three different parametric curve models for mean response over time were 
introduced. In practice, if we are not sure about which one to choose, we can use standard 
maximum likelihood (ML) to compare different regression models for the mean. Likelihood ratio 
test (LRT) is applied to compare nested models, where LRT test statistic can be compared to a 
chi-squared distribution with degrees of freedom equal to the difference between the number of 
parameters in the full and reduced models [33-35]. In the case that different models for mean 
response are not nested, their respective log-likelihoods can be directly compared. We expect a 
better fitting model with smaller -2 ML log-likelihood or Akaike’s information criterion (AIC) 
value [36, 37]. 
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2.3.2 Modeling the Covariance 
 
Another important aspect of modeling longitudinal data is to model the covariance 
structure [38, 39]. Statistical inferences may be severely affected by a misspecified covariance 
model, such as a great loss of efficiency for coefficients [40]. There are three main approaches 
that can be used. 
(1) “Unstructured” or arbitrary pattern of covariance. When the number of measurement 
occasions is relatively small with balanced designs, it is reasonable to allow the covariance 
matrix to be arbitrary, without imposition of any constrain for every single element [41]. With n 
measurement occasions, “unstructured” covariance matrix has 
( 1)
2
n n 
 parameters. As a result, 
the potential drawback for this covariance structure is that there are too many parameters need to 
be estimated, given the limited information, especially when the number of measurement 
occasions are large. Therefore, it is only suitable when n is relatively small. Also, it is not 
working well for the unbalanced data, which is quite common for the longitudinal designs in 
practice [42].  
(2) Covariate pattern models. Based on the data, there are some structures that can be 
built into the covariance by adopting a covariance pattern model, which might result in relatively 
parsimonious models for the covariance inferences. Some of the most widely used covariance 
pattern models for longitudinal data including compound symmetry, toeplitz, autoregressive, 
banded and exponential patterns [43].  
Compound symmetry covariance pattern assumes that the variance is constant across 
time and the correlation for all different observations is  . This strong assumptions about the 
variance and correlation are usually not valid for longitudinal data. Toeplitz pattern also assumes 
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constant variance across occasions and ,( , )ij i j k kCorr Y Y   for all j and k. Toeplitz is only 
appropriate when measures are made at equal or approximately equal intervals of time. Similarly, 
autoregressive pattern assumes constant variance across occasions as well and 
,( , )
k
ij i j kCorr Y Y   for all j and k. It’s only appropriate with equally or approximately equally 
spaced measurements. Banded pattern assumes correlation of the observations decays to zero 
beyond some specified interval. Banded pattern makes strong assumption about the quick 
correlation dropping to zero with increasing time span. Exponential pattern is a special case of 
autoregressive model when measurement occasions are not equally-spaced over time. It assumes 
the variance is constant across all measurement occasions and ( , ) ij ik
t t
ij ikCorr Y Y 

 , indicating 
that correlation between any pair of repeated measures decreases exponentially with the time 
separation between them.  
We should keep in mind that too little covariance structure might lead to redundant 
parameters to be estimated with limited amount of data, while too much structure tends to result 
in potential risk of model misspecification and subsequently misleading inferences. So, when 
attempting to impose any specific structure on the covariance, we need to obtain an optimal 
tradeoff between bias and variance. 
(3) Random effects covariance structure, which is introduced in the following part.  
Residual maximum likelihood (REML) can be used to compare different models for 
covariance structures because the main idea behind REML is to eliminate the parameters β from 
the likelihood so that it is defined only in terms of  [44, 45]. Similarly to the comparison of 
different models for mean response, in order to compare nested models for covariance, LRT 
based on REML log-likelihood can be obtained and a G
2
 statistic can be calculated, which 
follows a chi-square distribution with degrees of freedom equal to the difference between the 
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number of covariance parameters in full and reduced models. To compare non-nested models, 
their respective REML log-likelihoods or AIC values can be directly compared, where model 
with such smaller values is preferable.  
2.4 Linear Mixed Effect Model (Random Intercept Model) for Longitudinal Data 
 
In many cases of longitudinal studies, it is common that each individual has its own 
different subject-specific intercept over time. In order to account for this natural heterogeneity in 
the population, we should introduce a regression parameter that vary randomly from one 
individual to another. This is the motivation of introducing linear mixed effect model. Literal 
meaning of the term “mixed” denotes that model contains both fixed and random effect. The 
random intercept model can be presented as 'ij ij i ijY X b    , where   is a (p×1) vector of 
parameters, assumed to be shared by all individuals and are called fixed effects, ib is the random 
effects, which are subject-specific intercepts effects unique to each particular individual. The 
random effects, ib , are assumed to have a normal distribution with mean zero and variance 
2
b . 
The within-subject errors, ij , are assumed to have a normal distribution with mean zero and 
variance 2 [46, 47].  
Linear mixed effects model has its own appealing advantages. Firstly, because linear 
mixed effects model takes into account both fixed and random effects, the distinction among 
between-subject and within-subject variation in the longitudinal responses become explicit. 
Secondly, it can be used to predict how each individual response trajectories change over time. 
Thirdly, since time is treated as continuous, thus it is suitable for unbalanced longitudinal designs.  
In a linear mixed effect (random intercept) model, it is also true to model both mean 
response and covariance for the data. 
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2.4.1 Modeling Conditional and Marginal Mean 
 
In a random intercept model, there is an important distinction between the conditional 
and marginal means of Yij [48]. The conditional or subject-specific mean can be expressed by  
'( , )ij ij i ij iE Y X b X b  , while the marginal or population-averaged mean is 
'( )ij ij ijE Y X X  . 
For illustration, if we consider a simple linear mixed effects model with intercepts that vary 
randomly among individuals. That is, for the ith subject at the jth measurement occasion, the 
model is 1 2( )ij i ij ijY b Time      . In this model, the differences between conditional mean 
and marginal mean can be presented in the following figure. In Figure 2.5, the middle solid line 
represents the marginal mean of both individual A and B, it displays the change pattern of the 
marginal mean response over time. Two broken lines display how the conditional mean 
responses for the two specific individual A and B change with time. From this figure, we can 
observe that compared with population average 1  in this simple model, individual A has a 
“higher” baseline level of response 1( )ib  , indicating that subject A has a positive random 
intercept effect ib . Similarly, we see that subject B has a negative random intercept effect ib  
since B has a “lower” baseline level of response than the population. 
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Figure 2.5 Graphical representation of the marginal and conditional mean response over time and 
marginal and conditional covariance [29]. 
2.4.2 Modeling Conditional and Marginal Covariance 
 
Variation and covariance can also be defined relative to the conditional and marginal 
means. Consequently, we should also distinguish conditional and marginal covariance.  In a 
random intercept model ' ,ij ij i ijY X b    the conditional subject-specific variance is 
2
,( ) ( )ij ij i ijVar Y X b Var    , in contrast, the marginal variance of each response iY is 
' 2 2( ) ( ) ( ) .ij ij i ij i ij bVar Y Var X b Var b            Similarly, the marginal covariance 
between any pair of responses is 2( , )ij ik bCov Y Y   and the correlation is 
2
2 2
( , ) bij ik
b
Corr Y Y

 


[49]. Therefore, the introduction of a random intercept, bi, induces 
correlation among the repeated measurements in longitudinal data. In the same example as in 
figure 2.5, the conditional variance 2  is the variation of observations around the broken line. It 
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describes variation in a specific individual’s observations around its own mean. The marginal 
covariance describes variation of the observations with respect to the marginal mean, which is 
the variation and covariation of observations around the solid line. 
2.5 Statistical Analysis 
 
All the statistical analyses were conducted using SAS (version 9.2), SAS procedure, 
PROC MIXED were used to do the longitudinal data analysis. 
Hypothesis testing results with p-values of 0.05 or less were considered to be statistically 
significant.  
For ProCA1 and ProCA1B14 longitudinal dataset, in order to choose a fitting covariance 
structure, a maximal model for the mean response profile analysis was chosen at first. It included 
main effects of time, which were considered as categorical variables, and group, in addition to 
their interaction. Because time occasions in this dataset is relatively small, n=5, including 0, 10 
minutes, 30 minutes, 1440 minutes (1 day), 2880 minutes (2 days), and the design was balanced, 
unstructured covariance matrix was firstly under consideration. In addition, since the 
measurement occasions are not equally-spaced over time, an exponential covariance pattern also 
was considered in this case. Then, LRT based on REML was adopted to compare two different 
covariance pattern models since exponential covariance model is nested in the unstructured 
model. Given the choice of selected covariance model, mean response modeling should be taken 
into account. Covariate by time interactions, parametric curve for means are modeled as an 
explicit function of continuous time. Three different models for mean response were chosen, 
including linear trend over time model, linear splines model and quadratic trend over time model. 
ML log likelihood were used to compare nested and non-nested models for the mean response. 
The final form of the regression model both for mean response and covariance were constructed. 
    33 
For ProCA32 and Eovist dataset, a linear mixed effect model with random intercept was adopted 
to account for subject-specific effect that is unique to a particular individual.  
Model adequacy was evaluated using scatter plot of the transformed or scaled residuals 
versus the predicted values, where scaled residuals were obtained by Cholesky decomposition 
method to remove the correlation of multiple measurements of the same individual so that they 
mimic residuals from a standard linear regression [50]. A normal quantile plot of the transformed 
residuals was used to assess the normal distribution assumption and to identify outliers. In SAS, 
when the VCIRY option is used, marginal residuals will be scaled produced by the OUTPM 
option. Scaled residual plots and normal plots can be obtained for SAS/GRAPH users with ODS 
GRAPHICS ON option. 
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CHAPTER 3 RESULTS 
3.1 Results for ProCA1 and ProCA1B14 Data 
Figure 3.1 displays the T1-weighted spin echo MR imaging of PC3 and H441 xenograft 
mice tumor model with injection of ProCA1 or ProCA1B14 at each time point. In both tumors, it 
is clearly to observe the MRI intensity differences between two contrast agents groups along the 
study time.  
 
 
Figure 3.1 T1-weighted spin echo MR imaging of PC3 and H441 xenograft mice tumor. Top: T1-
weighted spin echo MR imaging of ProCA1 in PC3 and H441 xenograft mice tumor. Bottom: 
T1-weighted spin echo MR imaging of ProCA1B14 in PC3 and H441 xenograft mice tumor (Pu, 
unpublished data). 
 
3.1.1 Descriptive Statistics 
3.1.1.1 Covariance and Correlation 
 
Since the key feature of longitudinal data is heterogeneous variability, we first take a look 
at the variance-covariance matrix and correlation matrix of the data. Table 3.1 and 3.2 show the 
covariance and correlation matrix for the MRI intensity levels of ProCA1 group in PC3 
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xenograft mice tumor at five different time occasions. Table 3.3 and 3.4 show the covariance and 
correlation matrix for the MRI intensity levels of ProCA1B14 group in PC3 xenograft mice 
tumor at five different time occasions. Table 3.5 and 3.6 show the covariance and correlation 
matrix for the MRI intensity levels of ProCA1 group in H441 xenograft mice tumor at five 
different time occasions. Table 3.7 and 3.8 show the covariance and correlation matrix for the 
MRI intensity levels of ProCA1B14 group in H441 xenograft mice tumor at each time occasion. 
Based on these covariance and correlation matrices, we can observe that in each group with each 
type of tumor cell, the variability of the outcome is not constant from the beginning to the end of 
the study and repeated measures on the same individual are somehow correlated. Thus, two main 
assumptions of traditional linear regression, which are independence and constant variance, are 
both violated in this longitudinal study. Consequently, we are motivated to use specific 
procedure to analyze longitudinal data, allowing the dependent repeated measurements to have 
an unknown covariance structure. 
 
Table 3.1 Covariance matrix for the MRI intensity levels at pre-injection, 10 min, 30 min, 1day 
and 2 days post injection of 0.025 mmol/kg of ProCA1 with PC3 tumor cells. 
 
Covariance Matrix 
17.13 2.59 -0.33 -5.44 2.14 
2.59 22.32 -3.84 3.06 0.05 
-0.33 -3.84 8.52 -8.89 3.19 
-5.44 3.06 -8.89 14.67 -2.95 
2.14 0.05 3.19 -2.95 1.94 
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Table 3.2 Correlation matrix for the MRI intensity levels at pre-injection, 10 min, 30 min, 1day 
and 2 days post injection of 0.025 mmol/kg of ProCA1 with PC3 tumor cells. 
 
Correlation Matrix 
1.00 0.13 -0.03 -0.34 0.37 
0.13 1.00 -0.28 0.17 0.01 
-0.03 -0.28 1.00 -0.80 0.78 
-0.34 0.17 -0.80 1.00 -0.55 
0.37 0.01 0.78 -0.55 1.00 
 
 
Table 3.3 Covariance matrix for the MRI intensity levels at pre-injection, 10 min, 30 min, 1day 
and 2 days post injection of 0.025 mmol/kg of ProCA1B14 with PC3 tumor cells. 
 
Covariance Matrix 
5.55 11.89 -3.50 -3.08 -2.89 
11.89 33.80 -7.19 -9.69 -5.23 
-3.50 -7.19 2.58 2.00 2.20 
-3.08 -9.69 2.00 3.00 1.33 
-2.89 -5.23 2.20 1.33 2.07 
 
 
Table 3.4 Correlation matrix for the MRI intensity levels at pre-injection, 10 min, 30 min, 1day 
and 2 days post injection of 0.025 mmol/kg of ProCA1B14 with PC3 tumor cells. 
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Correlation Matrix 
1.00 0.87 -0.92 -0.75 -0.85 
0.87 1.00 -0.77 -0.96 -0.63 
-0.92 -0.77 1.00 0.72 0.95 
-0.75 -0.96 0.72 1.00 0.53 
-0.85 -0.63 0.95 0.53 1.00 
 
 
Table 3.5 Covariance matrix for the MRI intensity levels at pre-injection, 10 min, 30 min, 1day 
and 2 days post injection of 0.025 mmol/kg of ProCA1 with H441 tumor cells. 
 
Covariance Matrix 
0.65 -2.39 0.01 0.58 -0.64 
-2.39 11.47 12.47 0.76 2.19 
0.01 12.47 65.46 18.99 0.23 
0.58 0.76 18.99 8.27 1.06 
-0.64 2.19 0.23 1.06 7.05 
 
 
Table 3.6 Correlation matrix for the MRI intensity levels at pre-injection, 10 min, 30 min, 1day 
and 2 days post injection of 0.025 mmol/kg of ProCA1 with H441 tumor cells. 
 
Correlation Matrix 
1.00 -0.88 0.00 0.25 -0.30 
-0.88 1.00 0.46 0.08 0.24 
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0.00 0.46 1.00 0.82 0.01 
0.25 0.08 0.82 1.00 0.14 
-0.30 0.24 0.01 0.14 1.00 
 
Table 3.7 Covariance matrix for the MRI intensity levels at pre-injection, 10 min, 30 min, 1day 
and 2 days post injection of 0.025 mmol/kg of ProCA1B14 with H441 tumor cells. 
 
Covariance Matrix 
1.49 -2.80 0.37 -2.93 6.81 
-2.80 6.29 -0.31 8.34 -14.39 
0.37 -0.31 0.73 -0.45 0.73 
-2.93 8.34 -0.45 37.86 -16.85 
6.81 -14.39 0.73 -16.85 33.90 
 
 
Table 3.8 Correlation matrix for the MRI intensity levels at pre-injection, 10 min, 30 min, 1day 
and 2 days post injection of 0.025 mmol/kg of ProCA1B14 with H441 tumor cells. 
 
Correlation Matrix 
1.00 -0.92 0.36 -0.39 0.96 
-0.92 1.00 -0.15 0.54 -0.99 
0.36 -0.15 1.00 -0.09 0.15 
-0.39 0.54 -0.09 1.00 -0.47 
0.96 -0.99 0.15 -0.47 1.00 
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3.1.1.2 Mean Response (MRI intensity) 
 
Mean MRI intensity of 0.025 mmol/kg ProCA1 and 0.025 mmol/kg ProCA1B14 groups 
with PC3 tumor cells at 5 time occasions are shown in Table 3.9 and 3.10, respectively. Table 
3.11 and 3.12 show the mean MRI intensity of 0.025 mmol/kg ProCA1 and 0.025 mmol/kg 
ProCA1B14 groups with H441 tumor cells at each time occasion. The trends of mean MRI 
intensity over time for ProCA1 and ProCA1B14 groups with PC3 and H441 tumor cells are 
graphically represented in Figure 3.2 and 3.4, and timeplot for each individual response over 
each time occasion of 2 groups with PC3 and H441 tumors are showed in Figure 3.3 and 3.5. 
Based on the descriptive results shown below, we can see that the mean intensity at the very 
beginning (pre injection) for ProCA1 and ProCA1B14 groups are quite close, however, the 
overall trends for mean response over the study time are distinctly different within two groups, 
that is, the mean intensity of ProCA1B14 group is generally higher than that in ProCA1 group. In 
addition, the curves of the mean scale over time of two groups are not strict linear lines and the 
point of 1 day post injection (1440 min) is an obvious changing point. We can observe this trend 
in both two xenograft mice tumor models (PC3 and H441). 
 
Table 3.9 Mean MRI intensity levels at 0, 10 min, 30 min, 1 day and 2 days after injection of 
0.025 mmol/kg of ProCA1 with PC3 tumor cells. 
Mean MRI intensity of ProCA1 group with PC3 tumor 
Time (minute) Mean Std Dev 
0 2.11×10
-6
 4.14 
10 2.05 4.72 
30 5.31 2.92 
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1440 -3.92 3.83 
2880 3.56 1.39 
 
Table 3.10 Mean MRI intensity levels at 0, 10 min, 30 min, 1 day and 2 days after injection of 
0.025 mmol/kg of ProCA1B14 with PC3 tumor cells.  
Mean MRI intensity of ProCA1B14 group with PC3 tumor 
Time (minute) Mean Std Dev 
0 -1.51×10
-6
 2.36 
10 7.51 5.81 
30 4.68 1.60 
1440 38.61 1.73 
2880 28.92 1.44 
 
Figure 3.2 Timeplot of mean intensity pre injection and 10 min, 30 min, 1 day and 2 days post 
injection of ProCA1 and ProCA1B14 with PC3 tumor.  
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Figure 3.3 Timeplot of  intensity of each subject pre injection and 10 min, 30 min, 1 day and 2 
days post injection of ProCA1 and ProCA1B14 with PC3 tumor.  
 
Table 3.11 Mean MRI intensity levels at 0, 10 min, 30 min, 1 day and 2 days after injection of 
0.025 mmol/kg of  ProCA1 with H441 tumor cells.  
Mean MRI intensity of ProCA1 group with H441 tumor 
Time (minute) Mean Std Dev 
0 -5.53×10
-6
 0.80 
10 1.52 3.39 
30 1.80 8.09 
1440 -3.69 2.88 
2880 5.30 2.65 
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Table 3.12 Mean MRI intensity levels at 0, 10 min, 30 min, 1 day and 2 days after injection of 
0.025 mmol/kg of ProCA1B14 with H441 tumor cells.  
Mean MRI intensity of ProCA1B14 group with H441 tumor 
Time (minute) Mean Std Dev 
0 -3.60×10
-6
 1.22 
10 1.28 2.51 
30 5.88 0.85 
1440 32.97 6.15 
2880 17.52 5.82 
 
 
Figure 3.4 Timeplot of mean intensity pre injection and 10 min, 30 min, 1 day and 2 days post 
injection of ProCA1 and ProCA1B14 with H441 tumor.  
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Figure 3.5 Timeplot of intensity of each subject pre injection and 10 min, 30 min, 1 day and 2 
days post injection of ProCA1 and ProCA1B14 with H441 tumor.  
 
3.1.2 Statistical Modeling  
3.1.2.1 Effects of ProCA1 and ProCA1B14 with PC3 Tumor 
 
3.1.2.1a Covariance Modeling  
 
In order to choose a working covariance structure, a maximal model for mean response 
was constructed at first, where time was categorical, then LRT based on REML can be used to 
compare unstructured covariance and exponential pattern covariance models, the fit statistics are 
showed in table 3.13. Test statistic based on LRT is G
2
 = 225.1-185=40.1 with 13 (or 15 - 2) 
degrees of freedom (p=0.0001 <0.05). Thus, unstructured covariance provided an adequate fit to 
the data. 
 
Table 3.13 Fit statistics for unstructured covariance model and exponential pattern covariance 
model. 
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 -2 Res Log Likelihood AIC 
Unstructured Covariance 185 215 
Exponential Covariance 225.1 229.1 
 
3.1.2.1b Mean Response Modeling 
 
Given the choice of unstructured covariance, mean response should be modeled. 
Covariates by time interactions, mean response were modeled as an explicit function of 
continuous time. Three different models, including linear trend over time model, linear spline 
model, where time point 1440 minute was taken as a knot, and quadratic trend over time models 
were constructed and the corresponding fit statistics are presented in table 3.14. Using ML-based 
LRT, we got G
2 
= 241.7-215=26.7 with 2 degrees of freedom (p<0.0001) for comparing linear 
trend model with linear spline model, and thus conclude that the linear spline model fitted the 
data better than linear trend model. Similarly, test statistic for linear and quadratic trend model 
comparison was G
2 
= 241.7-214.9=26.8 with 2 degrees of freedom (p<0.0001), as a result, the 
quadratic trend model provided a more adequate fitting of the mean response over time than 
linear trend model. Next, we compared AIC values for non-nested models (linear spline and 
quadratic model), and concluded that the quadratic trend over time model fitted the data best in 
the three models. 
Table 3.14 Fit statistics for linear trend, linear spline and quadratic trend for mean response 
modeling with unstructured covariance matrix. 
 -2 log likelihood AIC 
Linear trend 241.7 279.7 
Linear spline 215 257 
     Quadratic trend 214.9 256.9 
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Therefore, the final model for MRI intensity pre and post injection of ProCA1 and 
ProCA1B14 with PC3 tumor mice is a quadratic trends over time model with an unstructured 
covariance matrix. Estimated regression coefficients, standard errors, and p-values based on the 
quadratic model are showed in table 3.15. 
Table 3.15 Solution for fixed effects in the final model (with PC3 tumor) 
Solution for Fixed Effects 
Effect group Estimate Standard Error DF t Value Pr > |t| 
Intercept 
 
3.8378 0.7244 8 5.30 0.0007 
group ProCA1B14 -0.5938 1.0245 8 -0.58 0.5781 
group ProCA1 0 . . . . 
time 
 
-0.01065 0.002572 8 -4.14 0.0032 
time
2
 
 
3.585E-6 0 8 Infty <.0001 
group × time ProCA1B14 0.05044 0.003637 8 13.87 <.0001 
  group × time ProCA1 0 . . . . 
group × time
2
 ProCA1B14 -0.00001 1.187E-6 8 -12.03 <.0001 
group × time
2
 ProCA1 0 . . . . 
 
The final model is: 
            
2 2
1 2 3 4 5 6ij i ij ij ij ij ijY Group Time Time Group Time Group Time               , 
where, Groupi = 
1if Group=ProCA1B14
0 if Group=ProCA1
 
 
 
  
            ij , are assumed to have a multivariate normal distribution with mean zero and 
covariance matrix denoted by iR  (
2
iR I , where I is a i in n  identity matrix).  
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Model for the mean intensity for subjects in control group (ProCA1) is:  
2 6 2
1 3 4( ) 3.585 10 0.01065 3.8378ij ij ij ij ijE Y Time Time Time Time  
       . 
For subjects in ProCA1B14 group, the model is:  
2 6 2
1 2 3 5 4 6( ) ( ) ( ) ( ) 6.415 10 0.03979 3.244ij ij ij ij ijE Y Time Time Time Time     
          
. 
Significance tests of variables in the model are presented in table 3.16, from which we 
can see that, aside from “group” effect, other variables are all significant (p-value<0.05) in the 
model. Based on the results, we’d like to answer three questions which are three main research 
interests of a longitudinal study. 
(1) Is there a group × time interaction effect?  
H0: no group×time interaction effect. 
Test-statistic for group×time effect is 192.28 with 1 degree of freedom, p-value < 0.0001. 
In addition, test-statistic for group×time
2
 term is 144.82 with 1 degree of freedom, p-value < 
0.0001. We should reject the null hypothesis and conclude that there is a significant group ×time 
interaction effect, indicating that the change of mean intensity in ProCA1 and ProCA1B14 
groups are significantly different over the study time. 
(2) Is there a time effect?  
H0: no time effect. 
Test-statistic for time effect is 64.14 with 1 degree of freedom, p-value < 0.0001. And 
test-statistic for time
2
 is 18.23, degree freedom is 1 with p-value=0.0027. We should reject the 
null hypothesis and conclude that there is a significant time effect, indicating that the mean 
intensity is significantly different upon the study time. 
(3) Is there a group effect?  
H0: no group effect. 
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Test-statistic=0.34 with 1 degree of freedom, p-value=0.5781. We fail to reject the null 
hypothesis and conclude that there is not a significant group effect, indicating good 
randomization. 
Table 3.16 Type 3 tests of fixed effects in the final model (with PC3 tumor). 
Type 3 Tests of Fixed Effects 
Effect Num DF Den DF Chi-Square F Value Pr > ChiSq Pr > F 
group 1 8 0.34 0.34 0.5622 0.5781 
time 1 8 64.14 64.14 <.0001 <.0001 
 time
2
 1 8 18.23 18.23 <.0001 0.0027 
group × time 1 8 192.28 192.28 <.0001 <.0001 
group × time
2
 1 8 144.82 144.82 <.0001 <.0001 
 
Figure 3.6 graphically represents the change of estimated mean intensity for ProCA1 and 
ProCA1B14 groups with PC3 tumor upon the study time based on the quadric trend over time 
model.  The figure clearly presents that mean responses of two groups both have a quadratic 
changing trend over time, however, mean intensity of ProCA1B14 group (green line) is much 
higher than that of ProCA1 group (red line), both starting from a similar beginning point (0 
minute). 
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Figure 3.6 Timeplot of estimated mean intensity for ProCA1 and ProCA1B14 groups with PC3 
tumor. 
 
The analysis of longitudinal study is not completed without an examination of the 
residuals. Since residuals from longitudinal data have their specific property, that is the 
components of the residuals are inherently correlated and do not necessarily have constant 
variance. As a result, standard residual diagnostics should not be taken. Instead, we can use 
transformed residuals (or called scaled residuals) achieved by Cholesky decomposition [50], to 
check the adequacy of a model. The graphs of the scaled residuals in Figure 3.7 indicate no 
appreciable departure from normality, nor any definite outlying observations. 
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Figure 3.7 Scaled residual plots of the model for effect comparison of ProCA1 and ProCA1B14 
with PC3 tumor. 
 
3.1.2.2 Effects of ProCA1 and ProCA1B14 with H441 Tumor 
 
Similar procedures and strategies were utilized to analyze the intensity data of ProCA1 
and ProCA1B14 with mice H441 tumor model. A quadratic trend over time model for mean 
response with unstructured covariance matrix also adequately fitted the data. Solution for fixed 
effects are showed in table 3.17 and tests for the effects are listed in table 3.18. Based on the 
output, we are confident to say that change of mean intensity in ProCA1 and ProCA1B14 groups 
with H441 tumor are significantly different over the study time.  
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Model for the mean intensity for subjects in control group (ProCA1) with H441 tumor is:  
2 6 2
1 3 4( ) 3.728 10 0.00872 0.334ij ij ij ij ijE Y Time Time Time Time  
       . 
For subjects in ProCA1B14 group with H441 tumor, the model is:  
2 6 2
1 2 3 5 4 6( ) ( ) ( ) ( ) 6.272 10 0.03789 0.0008.ij ij ij ij ijE Y Time Time Time Time     
          
 
Table 3.17 Solution for fixed effects in the final model (with H441 tumor). 
Solution for Fixed Effects 
Effect group Estimate Standard Error DF t Value Pr > |t| 
Intercept 
 
0.3340 0.1469 8 2.27 0.0525 
group ProCA1B14 -0.3348 0.2077 8 -1.61 0.1456 
group ProCA1 0 . . . . 
time 
 
-0.00872 0.003042 8 -2.87 0.0209 
time
2
 
 
3.728E-6 1.169E-6 8 3.19 0.0129 
group × time ProCA1B14 0.04670 0.004302 8 10.85 <.0001 
group × time ProCA1 0 . . . . 
group × time
2
 ProCA1B14 -0.00001 1.654E-6 8 -8.95 <.0001 
group × time
2
 ProCA1 0 . . . . 
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Table 3.18 Type 3 tests of fixed effects in the final model (with H441tumor). 
Type 3 Tests of Fixed Effects 
Effect Num DF Den DF Chi-Square F Value Pr > ChiSq Pr > F 
group 1 8 2.60 2.60 0.1070 0.1456 
time 1 8 46.23 46.23 <.0001 0.0001 
time
2
 1 8 10.16 10.16 0.0014 0.0129 
group × time 1 8 117.82 117.82 <.0001 <.0001 
group × time
2
 1 8 80.06 80.06 <.0001 <.0001 
 
Change of estimated mean intensity for ProCA1 and ProCA1B14 groups with H441 
tumor upon the study time is represented graphically in Figure 3.8, from which we are able to 
observe the similar trends as in PC3 cancer model, that is, based on similar starting points at 0 
minute, mean intensity of ProCAB14 group (green line) is much higher than that of ProCA1 
group (red line) with H441 tumor. 
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Figure 3.8 Timeplot of estimated mean intensity for ProCA1 and ProCA1B14 groups with H441 
tumor. 
 
 
Scaled residual plots are shown in Figure 3.9, from which we did not observe significant 
violations of normality assumption and outliers. 
 
 
Figure 3.9  Scaled residual plots of the model for effect comparison of ProCA1 and ProCA1B14 
with H441 tumor. 
3.2 Results for ProCA32 and Eovist Data 
          The comparison of liver MRI signal enhancement prior and post injection of same 
concentration (0.025mmol/kg) of ProCA32 and Eovist are showed in Figure 3.10A and intensity 
differences are represented graphically in Figure 3.10B. According to these figures, we are able 
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to observe intensity differences, and subsequently, we need to do statistical analysis to study the 
significance of the distinction. 
A B
 
Figure 3.10  Comparison of the liver MRI enhancement before and after injection of 
0.025mmol/kg of ProCA32 or Eovist [25]. 
 
3.2.1 Descriptive Statistics 
 
Mean liver MRI intensity of each group taken at corresponding time occasions are shown 
in table 3.19 (0.025 mmol/kg Eovist group), table 3.20 (0.0125 mmol/kg ProCA32 group) and 
table 3.21 (0.025 mmol/kg ProCA32 group), respectively. The graphical representation for mean 
responses of three different groups are plotted in Figure 3.11 in one panel, from which we are 
able to observe that the mean liver MRI intensity of ProCA32 groups had an increasing trend 
over the research time, while the mean intensity of 0.025 mmol/kg Eovist group increased from 
time 0 to 10 min and decreased from time 10 min to 50 min. Overall, 0.025 mmol/kg ProCA32 
group showed a relative higher mean intensity than the other 2 groups, especially at around 15 
min and 45 min. A timeplot for each individual response over time is displayed in Figure 3.12, 
we can observe that individuals have their own subject specific mean response. Therefore, 
constructing a model with intercepts that can vary randomly among individuals to account for 
sources of natural heterogeneity in the population, was motivated for this dataset.  
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Table 3.19 Mean liver MRI intensity levels at 0, 10 min and 50 min after injection of 0.025 
mmol/kg of Eovist. 
Mean liver MRI intensity of 0.025 mmol/kg Evoaist group 
Time (minute) Mean Std Dev 
0 0.0017 0.00030 
10 0.0024 0.00049 
50 0.0020 0.00020 
 
Table 3.20 Mean liver MRI intensity levels at 0, 17 min and 48 min after injection of 0.0125 
mmol/kg of ProCA32. 
Mean liver MRI intensity of 0.0125 mmol/kg ProCA32 group 
Time (minute) Mean Std Dev 
0 0.0016 0.00022 
17 0.0022 0.00032 
48 0.0023 0.00029 
 
Table 3.21 Mean liver MRI intensity levels at 0, 16 min and 46 min after injection of 0.025 
mmol/kg of ProCA32. 
Mean liver MRI intensity of 0.025 mmol/kg ProCA32 group 
Time (minute) Mean Std Dev 
0 0.0019 0.00021 
16 0.0031 0.00055 
46 0.0032 0.00053 
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Figure 3.11 Time plot of mean liver MRI intensity before and after injection of 0.025 mmol/kg 
of Eovist (black line), 0.0125 mmol/kg of ProCA32 (red line) and 0.025 mmol/kg of ProCA32 
(blue line). 
 
 
 
Figure 3.12 Time plot of liver MRI intensity against time. 
    56 
3.2.2 Statistical Modeling 
To account for a subject-specific intercept for each individual, a linear mixed effect 
model including random intercept for unbalanced data was considered: 
           1 2 3 1 4 2 5 1 6 2ij ij ij ij i ijY Time Group Group Time Group Time Group b                , 
where: 
Group1=
0.025 mmol/kg P=1 if Group=
=0 otherwise
roCA32 
 

; 
Group2=
0.0125 mmol/kg P=1 if Group=
=0 otherwise
roCA32 
 

; 
           2(0, )i bb N   is the random subject error; 
2(0, )ij N  are within-subject measurement          
errors; ib and ij are mutually independent. 
Here, 0.025 mmol/kg Eovist group is set as the control group, model for each group is 
listed as follows: 
0.025 mmol/kg Eovist group: 1 2( )ij i ij ijY b Time       
                                                1 2( )ij ijE Y Time   Marginal mean 
                                                1 2( ) ( )ij i i ijE Y b b Time    Conditional mean  
0.0125 mmol/kg ProCA32 group: 1 4 2 6( ) ( )ij i ij ijY b Time           
                                                      1 4 2 6( ) ( ) ( )ij ijE Y Time       Marginal mean 
                                                      1 4 2 6( ) ( ) ( )ij i i ijE Y b b Time        Conditional mean  
0.025 mmol/kg ProCA32 group: 1 3 2 5( ) ( )ij i ij ijY b Time           
                                                     1 3 2 5( ) ( ) ( )ij ijE Y Time       Marginal mean 
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                                         1 3 2 5( ) ( ) ( )ij i i ijE Y b b Time        Conditional mean     
Estimated regression coefficients for fixed effects and standard errors for the ProCA32 
and Eovist data are showed in table 3.22. Estimated covariance of the random effects for the 
data are showed in table 3.23. 
Table 3.22 Solution for fixed effects based on the random intercept model. 
Solution for Fixed Effects 
Effect Group Estimate Standard Error DF t Value Pr > |t| 
Intercept 
 
0.002011 0.000137 21 14.70 <.0001 
Time 
 
8.494E-7 3.856E-6 45 0.22 0.8267 
Group 3 0.000172 0.000199 45 0.87 0.3910 
Group 2 -0.00026 0.000199 45 -1.32 0.1946 
Group 1 0 . . . . 
Time*Group 3 0.000026 5.827E-6 45 4.38 <.0001 
Time*Group 2 0.000012 5.696E-6 45 2.04 0.0475 
Time*Group 1 0 . . . . 
 
Table 3.23 Estimated covariance of the random effects for the data. 
Covariance Parameter Estimates 
Cov Parm Estimate 
Var(bi) 4.656E-8 
Residual 1.666E-7 
 
Interpretation of marginal mean and conditional mean: 
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The estimated intercept 
1ˆ =0.002011 is the average liver MRI intensity pre-injection of 
0.025 mmol/kg Eovist. The estimated intercept ( 1 4
ˆ ˆ  )=0.001751, is the average liver MRI 
intensity before injecting 0.0125 mmol/kg ProCA32. (
1 3
ˆ ˆ  )=0.002183, is the mean intercept 
of 0.025 mmol/kg ProCA32 group at time 0. 
The slope 2ˆ =8.494×10
-7
 is the average rate of change in liver MRI intensity of 0.025 m
mol/kg Eovist group. The slope ( 2 6
ˆ ˆ  )=1.28494×10-5 is the average rate of change in liver M
RI intensity in 0.0125 mmol/kg ProCA32 group. The slope ( 2 5
ˆ ˆ  )=2.68494×10-5 is the averag
e rate of change in liver MRI intensity in 0.025 mmol/kgProCA32 group.  
Considering the subject specific intercept, the intercepts for the ith
 
subject in 0.025 
mmol/kg Eovist group, 0.0125 mmol/kg ProCA32 and 0.025 mmol/kg ProCA32 groups are 
( 0.002011 )ib ,  ( 0.001751 )ib  and ( 0.002183 )ib , respectively. 1( )ib   have mean β1 and 
variance 2b =4.656×10
-8
. Under the assumption of normality, we expect 95% of the subject-
specific intercepts, 1( )ib  , in 0.025 mmol/kg Eovist group, to lie between 
1 1.96 b   =[0.001588, 0.002434]. 
In a similar fashion, we expect 95% of the subject-specific intercepts, ( 1 4 ib   ), in 
0.0125 mmol/kg ProCA32 group, to lie between 1 4( ) 1.96 b     =[0.001328, 0.002174]. A 
95% confidence interval for specific intercepts in 0.025 mmol/kg ProCA32 group is 
1 3( ) 1.96 b      = [0.00176, 0.002606].   
Interpretation of conditional variance and marginal variance: 
In this linear mixed effect model (random intercepts model), the conditional variance is:   
,
2( ) var( )ij iij ijVar Y X b   ∣ =1.666×10
-7
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The marginal variance is:  
 
            
2 2)( bijVar Y     =4.656×10
-8
+1.666×10
-7
 = 2.1316×10
-7 
           2( , )ij ik bCov Y Y  =4.656×10
-8
 
          
2 8
2 2 7
4.6
2.1316 10
56 10
( , ) bij ik
b
Corr Y Y

  

 



= 0.2185 
 
Interpretation of prediction for bi:  
One of the advantages of a linear mixed effect model is that we are able to get the best 
linear unbiased predictor (BLUP) of subject-specific effects bi for every single individual, which 
are showed in Table 3.24. Thus, the predicted value of each subject-specific intercept can be 
obtained for this dataset. For example, if we are interested in the first subject (ID=17) in 0.025 
mmol/kg ProCA32 group, its empirical BLUP intercept is 1 3 17b   =0.002183-
0.00041=0.001773. 
Table 3.24  Solution for random effects (bi) in the model. 
Solution for Random Effects 
Effect ID Estimate Std Err Pred DF t Value Pr > |t| 
Intercept 17 -0.00041 0.000167 45 -2.47 0.0174 
Intercept 18 -0.00016 0.000167 45 -0.96 0.3420 
Intercept 19 0.000100 0.000167 45 0.60 0.5524 
Intercept 20 0.000036 0.000167 45 0.21 0.8321 
Intercept 21 0.000161 0.000167 45 0.96 0.3416 
Intercept 22 0.000051 0.000167 45 0.30 0.7634 
Intercept 23 0.000151 0.000167 45 0.90 0.3710 
Intercept 24 0.000075 0.000167 45 0.45 0.6544 
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Intercept 9 -0.00016 0.000167 45 -0.94 0.3526 
Intercept 10 -0.00002 0.000167 45 -0.12 0.9063 
Intercept 11 9.089E-6 0.000167 45 0.05 0.9569 
Intercept 12 -0.00006 0.000167 45 -0.38 0.7023 
Intercept 13 0.000011 0.000167 45 0.07 0.9456 
Intercept 14 0.000143 0.000167 45 0.85 0.3979 
Intercept 15 -3.11E-6 0.000167 45 -0.02 0.9853 
Intercept 16 0.000081 0.000167 45 0.48 0.6305 
Intercept 1 -0.00027 0.000167 45 -1.59 0.1181 
Intercept 2 -0.00010 0.000167 45 -0.61 0.5420 
Intercept 3 -0.00003 0.000167 45 -0.20 0.8454 
Intercept 4 0.000147 0.000167 45 0.88 0.3848 
Intercept 5 0.000020 0.000167 45 0.12 0.9045 
Intercept 6 0.000062 0.000167 45 0.37 0.7128 
Intercept 7 0.000060 0.000167 45 0.36 0.7227 
Intercept 8 0.000113 0.000167 45 0.68 0.5013 
 
Significance tests of fixed effects in the model are presented in table 3.25 and we can see 
that, in this longitudinal study, there’s no group effect (p-value=0.1130), indicating three groups 
did not have significantly different baseline MRI intensities prior injection of contrast agents. We 
also observed that there is a time effect (p-value < 0.0001) and a group × time interaction effect 
(p-value=0.0003), which means that the changing pattern of mean intensity in three groups are 
significantly different over the study time. The next question is how the change rate differ in 
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different groups? We can get answers from the pair-wise mean liver MRI intensities comparison 
of  three groups, shown in table 3.26, that is, there did not appear to be differences between the 
injection of 0.0125mmol/kg ProCA32 and 0.025 mmol/kg Eovist in their pattern of  change in 
mean liver MRI intensity along the study time. However, injection of 0.025 mmol/kg ProCA32 
resulted in significantly higher liver intensity enhancement than other two groups along the study 
time. 
Table 3.25 Significance tests of fixed effects (time, group, time × group interaction) in the 
model. 
Type 3 Tests of Fixed Effects 
Effect Num DF Den DF Chi-Square F Value Pr > ChiSq Pr > F 
Time 1 45 30.52 30.52 <.0001 <.0001 
Group 2 45 4.58 2.29 0.1014 0.1130 
Time*Group 2 45 19.16 9.58 <.0001 0.0003 
 
Table 3.26 Pair-wise mean intensity comparison in 3 groups. 
Differences of Least Squares Means 
Effect Group _Group Estimate 
Standard 
Error 
DF 
t 
Value 
Pr > |t| 
Group 
0.025 mmol/kg 
ProCA32 
0.0125 mmol/kg 
ProCA32 
0.000724 0.000160 45 4.53 <.0001 
Group 
0.025 mmol/kg 
ProCA32 
0.025 mmol/kg 
Eovist 
0.000702 0.000160 45 4.40 <.0001 
Group 0.0125 mmol/kg 0.025 mmol/kg -0.00002 0.000160 45 -0.13 0.8948 
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ProCA32 Eovist 
 
For the purpose of model adequacy checking, scaled residual plots are presented in 
Figure 3.13. The graphs do not indicate any appreciable violation of normality assumption and 
any definite outlier observations. 
 
Figure 3.13 Scaled residual plots of the model for comparison of ProCA32 and Eovist in liver 
MRI signal enhancement effects. 
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CHAPTER 4 CONCLUSIONS 
This thesis mainly focused on two sets of longitudinal data analysis. According to the 
structure and quality of the data, specific statistical analysis methods were utilized and 
statistically significant results were obtained. This study is an application of statistics into the 
field of Chemistry and Biology. It will benefit the researches to comprehend and interpret the 
experimental results better in a statistical aspect. The results will help researchers to make 
inferences and statements using the information from the single study for the larger population.  
In the first dataset, to compare the MRI signal enhancement in PC3 and H441 tumors 
prior and post injection of ProCA1 and ProCA1B14, a quadratic trend over time model with an 
unstructured covariance matrix was constructed for both tumor types. The results showed that 
after injection of ProCA1B14, which was designed to have abilities to target biomarker GRPR,  
the MRI intensities that were measured in PC3 and H441 xenograft mice tumor were 
significantly higher than those with ProCA1 at each time point post injection. This result 
indicates that this newly designed protein-based MRI contrast agent, ProCA1B14, is capable to 
specifically target prostate cancer and small cell lung cancer cells in the mice xenograft tumor 
models which express high level of GRPR, and to produce an MR image of these specific 
cancers. Thus, ProCA1B14 has the great potential to be a tumor specific contrast agent. It has a 
bright future to be applied in clinical diagnosis and treatment for specific high GRPR expressed 
tumors, such as tumor location and tumor size detection, and tumor progression evaluation, etc. 
The second dataset is for comparing liver MRI enhancement after injection of ProCA32 
and Eovist in mice. A random intercept effect model was constructed and the test results showed 
that lower concentration (0.0125 mmol/kg) of ProCA32 and 0.025 mmol/kg of Eovist did not 
have significant difference in liver MRI intensity generation along the study time, however, the 
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injection of same concentration of ProCA32 and Eovist (0.025 mmol/kg) resulted in significantly 
different liver MRI enhancement, that is, 0.025mmol/kg ProCA32 led to significantly higher 
liver MRI intensity at 10 min and 50 min post injection of the contrast agent. Therefore, 
appropriate concentration of ProCA32 has a great potential to be a promising MRI contrast agent 
for liver imaging in clinical application. 
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